SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form PRE 14A - Other preliminary proxy statements:
SEC Accession No. 0001047469-18-006094
Filing Date
2018-09-10
Accepted
2018-09-10 16:36:23
Documents
4
Period of Report
2018-09-10

Document Format Files

Seq Description Document Type Size
1 PRE 14A a2236660zpre14a.htm PRE 14A 171794
2 G271152BGI001.GIF g271152bgi001.gif GRAPHIC 183510
3 G271152BGI002.GIF g271152bgi002.gif GRAPHIC 112593
4 G832816.JPG g832816.jpg GRAPHIC 21180
  Complete submission text file 0001047469-18-006094.txt   610150
Mailing Address 1000 CONTINENTAL DRIVE SUITE 600 KING OF PRUSSIA PA 19406
Business Address 56 FITZWILLIAM SQUARE DUBLIN L2 2 (610) 816-6640
Nabriva Therapeutics plc (Filer) CIK: 0001641640 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L2 | Fiscal Year End: 1231
Type: PRE 14A | Act: 34 | File No.: 001-37558 | Film No.: 181063164
SIC: 2834 Pharmaceutical Preparations